On October 16, 2025 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis’ highly sensitive molecular residual disease (MRD) test, NeXT Personal, is a useful tool in assessing the maintenance treatment response post-CRT in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new LAURA analysis will be presented at the ESMO (Free ESMO Whitepaper) 2025 Conference in Berlin, Germany, demonstrating key findings for NeXT Personal:
Treatment monitoring: Osimertinib treatment led to MRD clearance in most patients with post-chemoradiotherapy (post-CRT) MRD, demonstrating the utility of ctDNA for monitoring the maintenance therapy response
Lead time to progression: NeXT Personal detected MRD progression with a median lead time of 5 months ahead of Blinded Independent Central Review (BICR) assessed disease progression
"This study from AstraZeneca shows how ultrasensitive ctDNA detection enabled by NeXT Personal enables precise tracking of the maintenance treatment response post-CRT during clinical trials. It is a good example of how AstraZeneca and our other biopharma partners are taking advantage of our ultrasensitive assay to gain new insights into their clinical studies," said Richard Chen, Chief Medical Officer and EVP of R&D at Personalis.
The LAURA trial (NCT03521154) is a global, randomized, placebo-controlled, double-blind, multi-center study of osimertinib following chemoradiation for patients with unresectable EGFRm NSCLC.
This collaboration also builds on previous work with AstraZeneca, showing the importance of highly sensitive ctDNA analysis for tracking treatment response and predicting cancer recurrence. This includes a recent publication of Phase 3 CALLA cervical cancer study results showing that NeXT Personal detected traces of cancer DNA in patients with locally advanced cervical cancer up to ~16 months ahead of standard of care imaging, and a recent presentation at the IASLC 2025 World Conference on Lung Cancer on the NeoADAURA study demonstrating that NeXT Personal can be a more sensitive and accurate measure of MRD in the neoadjuvant setting.
(Press release, Personalis, OCT 16, 2025, View Source [SID1234656720])